WHAT: An estimated ten million Americans suffer from osteoporosis, and another 34 million Americans are at risk of developing the disease, which is characterized by a severe loss of bone mineral density, fragile bones and an increased risk of hip, spine and wrist fractures. The basic mechanism behind osteoporosis involves an imbalance between bone mineral formation and loss, but the detailed biological processes that lead to this imbalance are not completely understood. Now researchers at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), and colleagues are reporting new insights into the biology of bone loss based on a study of 14 people with a rare genetic disorder called X-linked Hyper IgM Syndrome.
X-linked Hyper IgM Syndrome strikes about one in a million American--all males--and is caused by a deficiency in an important immune system protein known as CD40 ligand. This protein is crucial for the development and maturation of immune cells, and without it people with X-linked Hyper IgM Syndrome are susceptible to a range of opportunistic infections. Last year, an NIAID doctor treating children with this disease observed that several of them sustained unexplained rib fractures that he hypothesized could be, like osteoporosis, caused by a loss of bone mineral density. A new study, published online this week, confirms this unexpected connection. CD40 ligand appears to regulate cells that secrete chemicals that block bone metabolism, and the loss of this protein in people with X-linked Hyper IgM Syndrome appears to accelerate bone loss. The next step, say the researchers, is to determine whether experimental treatments designed to correct the immune deficiency of X-linked Hyper IgM Syndrome can also reverse the bone loss. If so, the knowledge gained from these studies may benefit people at risk of developing osteoporosis.
ARTICLE: "Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis." E Lopez-Granados et al., Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.0605715104 (2007). This study was conducted by scientists at NIAID, the National Cancer Institute, the NIH Clinical Center, and Shriners Hospital at McGill University in Montreal.
SPOKESPERSON: Ashish Jain, M.D., Clinical Investigator, Laboratory of Host Defenses, NIAID Division of Intramural Research, is available to comment on the study's findings.
CONTACT: To schedule interviews, contact Jason Bardi in the NIAID News and Public Information Branch, (301) 402-1663, firstname.lastname@example.org.
NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.
The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.